Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
Recruiting in Palo Alto (17 mi)
+17 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Approved in 5 Jurisdictions
Trial Summary
What is the purpose of this trial?
To compare the efficacy and safety of orally administered didanosine (ddI) with orally administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical deterioration despite treatment with AZT.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Dapsone.
Erythropoietin.
Colony-Stimulating Factors.
See 5 more
Treatment Details
Interventions
- Didanosine (Nucleoside Reverse Transcriptase Inhibitor)
- Zidovudine (Nucleoside Reverse Transcriptase Inhibitor)
Zidovudine is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
🇪🇺 Approved in European Union as Retrovir for:
- HIV/AIDS
🇺🇸 Approved in United States as Retrovir for:
- HIV/AIDS
- Prevention of mother-to-child transmission of HIV
🇨🇦 Approved in Canada as Retrovir for:
- HIV/AIDS
🇯🇵 Approved in Japan as Retrovir for:
- HIV/AIDS
🇨🇭 Approved in Switzerland as Retrovir for:
- HIV/AIDS
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
AIDS Research Consortium of AtlantaAtlanta, GA
Univ of Pennsylvania / HIV ClinicPhiladelphia, PA
Univ of Texas Southwestern Med Ctr of DallasDallas, TX
Univ TX Galveston Med BranchGalveston, TX
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Trials
2731
Patients Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia